Cargando…
Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
Autores principales: | Andtbacka, Robert HI, Curti, Brendan D, Hallmeyer, Sigrun, Feng, Zipei, Paustian, Christopher, Bifulco, Carlo, Fox, Bernard, Grose, Mark, Shafren, Darren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649439/ http://dx.doi.org/10.1186/2051-1426-3-S2-P343 |
Ejemplares similares
-
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022) -
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014) -
Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
por: Yuan, Min, et al.
Publicado: (2015) -
Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015) -
An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
por: Mougdil, Tarsem, et al.
Publicado: (2015)